Identification of drug resistance-related proteins in pancreatic cancer by SILAC quantitative proteomic approach.

2014 Fiscal Year Final Research Report

• Project/Area Number: 24501338
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Tumor diagnosis
• Research Institution: Chiba University
• Principal Investigator: SATOH Mamoru 千葉大学, 医学部附属病院, 寄附研究部門教員 (20401002)
• Co-Investigator(Kenkyū-buntansha): NOMURA Fumio 千葉大学, 大学院医学研究院, 教授 (80164739) ; MIYAZAKI Masaru 千葉大学, 大学院医学研究院, 教授 (70166156) ; YOSHITOMI Hideyuki 千葉大学, 医学部附属病院, 講師 (60375631) ; SOGAWA Kazuyuki 麻布大学, 生命・環境化学部, 講師 (50436440)
• Co-Investigator(Renkei-kenkyūsha): KODERA Yoshio 北里大学, 理学部, 准教授 (60265733) ; TAKANO Shigetsugu 千葉大学, 医学部附属病院, 助教 (20436380)
• Research Collaborator: KAWASHIMA Yusuke 理化学研究所, 統合生命医科学研究センター, 研究員
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: プロテオーム解析

Outline of Final Research Achievements

In this study, we employed a quantitative proteomics approach using stable isotope labeling with amino acids in cell culture (SILAC) followed by mass spectrometry to quantify changes in protein levels between gemcitabine resistant and sensitive pancreatic cancer cells. Proteins were extracted with cell fractionation and difference of solubilization. 344 (cell fractionation) and 118 (difference of solubilization) proteins were shown more than 2-fold change between the resistant and sensitive cell lines. Expression ratio of 40 proteins were confirmed by WB. 35 proteins were indicated more than 2-fold change by secretome analysis.

Free Research Field

総合領域